BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15944291)

  • 1. Enhanced expression of CD20 in human tumor B cells is controlled through ERK-dependent mechanisms.
    Wojciechowski W; Li H; Marshall S; Dell'Agnola C; Espinoza-Delgado I
    J Immunol; 2005 Jun; 174(12):7859-68. PubMed ID: 15944291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways.
    Li H; Wojciechowski W; Dell'Agnola C; Lopez NE; Espinoza-Delgado I
    J Immunol; 2006 Sep; 177(6):3554-63. PubMed ID: 16951314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
    Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
    Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
    Vega MI; Huerta-Yepez S; Jazirehi AR; Garban H; Bonavida B
    Oncogene; 2005 Dec; 24(55):8114-27. PubMed ID: 16103877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
    Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
    Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
    Shan D; Ledbetter JA; Press OW
    Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines.
    Cittera E; Onofri C; D'Apolito M; Cartron G; Cazzaniga G; Zelante L; Paolucci P; Biondi A; Introna M; Golay J
    Cancer Immunol Immunother; 2005 Mar; 54(3):273-86. PubMed ID: 15449038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
    Thomas A; Pepper C; Hoy T; Bentley P
    Leuk Lymphoma; 2004 May; 45(5):997-1008. PubMed ID: 15291360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis.
    Hofmeister JK; Cooney D; Coggeshall KM
    Blood Cells Mol Dis; 2000 Apr; 26(2):133-43. PubMed ID: 10753604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
    Suzuki E; Umezawa K; Bonavida B
    Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies.
    Winiarska M; Bojarczuk K; Pyrzynska B; Bil J; Siernicka M; Dwojak M; Bobrowicz M; Miazek N; Zapala P; Zagozdzon A; Krol M; Syta A; Podszywalow-Bartnicka P; Pilch Z; Dabrowska-Iwanicka A; Juszczynski P; Efremov DG; Slabicki M; Zenz T; Le Roy A; Olive D; Rygiel TP; Leusen JH; Golab J
    MAbs; 2014; 6(5):1300-13. PubMed ID: 25517315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
    Jazirehi AR; Vega MI; Bonavida B
    Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
    Shan D; Gopal AK; Press OW
    Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B
    Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate.
    Sieber S; Gdynia G; Roth W; Bonavida B; Efferth T
    Int J Oncol; 2009 Jul; 35(1):149-58. PubMed ID: 19513562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
    Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
    Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
    Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
    Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.